Stories about Debiopharm's

Subscribe to Debiopharm's

17.09.2020 – 09:00

Debiopharm International SA
DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS

Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
One document
more
07.07.2020 – 14:00

Debiopharm International SA
NUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM

Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...

more
10.06.2020 – 09:00

Debiopharm International SA
Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders

[Ort] (ots) - Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome Debiopharm ( http://www.debiopharm.com ), a Swiss biopharmaceutical company, announced today an exclusive license agreement and ...

more
27.02.2020 – 14:32

Debiopharm International SA
FDA grants Breakthrough Therapy Designation for Debiopharm's novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

Lausanne (ots) - - There have been no newly approved therapies over the last 25 years for "high risk" locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients - The FDA decision was based on the compelling magnitude of the clinically phase II findings in combination with chemo-radiotherapy ...

more
08.01.2020 – 14:00

Debiopharm International SA
Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...

more
30.09.2019 – 10:00

Debiopharm International SA
Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

Lausanne (ots) - Late breaking abstract results presented today at ESMO with chemo-radio sensitizer Debio 1143 present a promising breakthrough strategy to improve the front-line treatment of H&N cancer patients Debiopharm, a Swiss-based global biopharmaceutical company, presented today, at the ESMO Congress ...

more
09.07.2019 – 09:00

Debiopharm International SA
Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...

more

Research

Info

Topics

Country / Language

Presseportal App

Stories about Debiopharm's

17.09.2020 – 09:00

DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS

07.07.2020 – 14:00

NUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM

10.06.2020 – 09:00

Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders

27.02.2020 – 14:32

FDA grants Breakthrough Therapy Designation for Debiopharm's novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

08.01.2020 – 14:00

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

30.09.2019 – 10:00

Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

09.07.2019 – 09:00

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

Stories about Debiopharm's

From

To

17.09.2020 – 09:00

DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS

07.07.2020 – 14:00

NUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM

10.06.2020 – 09:00

Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders

27.02.2020 – 14:32

FDA grants Breakthrough Therapy Designation for Debiopharm's novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer

08.01.2020 – 14:00

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

30.09.2019 – 10:00

Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

09.07.2019 – 09:00

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases